Nathan Rice

Stock Analyst at Piper Sandler

(2.88)
# 1,849
Out of 5,090 analysts
60
Total ratings
50%
Success rate
8.33%
Average return

Stocks Rated by Nathan Rice

First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $39.85
Upside: +20.45%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $34.39
Upside: +22.13%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $29.19
Upside: +19.90%
Bank First
Oct 23, 2025
Maintains: Neutral
Price Target: $137$142
Current: $129.86
Upside: +9.35%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $75.63
Upside: -2.16%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $129.69
Upside: -35.23%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $157.21
Upside: +25.31%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $21.90
Upside: -58.90%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $714.10
Upside: -39.08%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $265.44
Upside: -12.22%
Initiates: Neutral
Price Target: $83
Current: $38.34
Upside: +116.48%
Initiates: Overweight
Price Target: $15
Current: $19.62
Upside: -23.55%